Heidi L. Gregg, CRNP

Heidi Gregg practices at Clearfield-Jefferson Primary Care Associates in Du Bois, Pennsylvania.

Heidi Gregg's NPI, 1801165006, was assigned on December 19, 2011. Heidi Gregg holds Pennsylvania license SP011797.

Heidi Gregg's primary practice is Clearfield-Jefferson Primary Care Associates, at 33 Beaver Dr, Du Bois, PA 15801 in Clearfield County. The practice phone is (814) 503-8070.

Heidi Gregg's primary practice is Clearfield-Jefferson Primary Care Associates in Du Bois, Pennsylvania. Heidi Gregg is also affiliated with Penn Highlands DuBois. The medical group on file is Clearfield-Jefferson Primary Care Associates. Dmand AI also links Heidi Gregg to 4 more hospitals, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Heidi Gregg practices, 6 sites in all. Vendor and product names are available with a free account.

Family is Heidi Gregg's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Heidi Gregg is licensed in Pennsylvania.

CMS counts 269 Medicare patients who saw Heidi Gregg in 2024. The largest group is 65 to 74, with 113 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Heidi Gregg's median patient age at 70, with 56% women.

In 2024, Heidi Gregg wrote 1,771 Medicare Part D claims for 429 patients. 55% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Heidi Gregg for performance year 2024, reported as part of a group. Heidi Gregg accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Heidi Gregg as offering telehealth.

CMS Open Payments shows 53 general payments to Heidi Gregg from 16 drug and device companies in 2025. Food and beverage make up the largest share, 92% of the total. AstraZeneca Pharmaceuticals LP paid the most, $265.